Dianthus Therapeutics (DNTH) Equity Ratio: 2017-2025
Historic Equity Ratio for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to 0.95.
- Dianthus Therapeutics' Equity Ratio fell 0.79% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year decrease of 0.79%. This contributed to the annual value of 0.94 for FY2024, which is 0.12% up from last year.
- As of Q3 2025, Dianthus Therapeutics' Equity Ratio stood at 0.95, which was up 1.81% from 0.93 recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Equity Ratio ranged from a high of 0.97 in Q1 2024 and a low of -0.78 during Q2 2023.
- Over the past 3 years, Dianthus Therapeutics' median Equity Ratio value was 0.94 (recorded in 2024), while the average stood at 0.65.
- The largest annual percentage gain for Dianthus Therapeutics' Equity Ratio in the last 5 years was 537.69% (2023), contrasted with its biggest fall of 200.88% (2023).
- Over the past 4 years, Dianthus Therapeutics' Equity Ratio (Quarterly) stood at -0.53 in 2022, then skyrocketed by 276.32% to 0.94 in 2023, then rose by 0.12% to 0.94 in 2024, then dropped by 0.79% to 0.95 in 2025.
- Its last three reported values are 0.95 in Q3 2025, 0.93 for Q2 2025, and 0.94 during Q1 2025.